Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
As of today (2026-08-07), the Trailing Annual Dividend Yield of Obsidian Therapeutics is 0.00%.
The historical rank and industry rank for Obsidian Therapeutics's Dividend Yield % or its related term are showing as below:
OBX's Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.285 * Ranked among companies with meaningful Dividend Yield % only.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Obsidian Therapeutics Dividend Yield % Related Terms
Obsidian Therapeutics Dividend Yield % Historical Data
* Premium members only.
The historical data trend for Obsidian Therapeutics's Dividend Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Obsidian Therapeutics Dividend Yield % Chart
Obsidian Therapeutics Annual Data
Trend
Dec24
Dec25
Dividend Yield %
0.00
0.00
Obsidian Therapeutics Semi-Annual Data
Dec24
Dec25
Dividend Yield %
0.00
0.00
OBX vs : Dividend Yield % Comparison
For the Biotechnology subindustry, Obsidian Therapeutics's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Obsidian Therapeutics Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Obsidian Therapeutics's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Obsidian Therapeutics's Dividend Yield % falls into.
Obsidian Therapeutics (OBX) has a Dividend Yield % of 0.00% as of Aug. 07, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on Obsidian Therapeutics and its competitors.
Is Obsidian Therapeutics' Dividend Yield % too high?
Obsidian Therapeutics' current Dividend Yield % is 0.00%. Overall, Obsidian Therapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Obsidian Therapeutics' Dividend Yield % compare to ?
Obsidian Therapeutics' Dividend Yield % of 0.00% can be compared against companies in the Biotechnology industry. The industry median Dividend Yield % is 1.29. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Biotechnology company?
The median Dividend Yield % among Biotechnology companies is 1.29, based on 150 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on Obsidian Therapeutics and its competitors. For the Biotechnology industry, the median Dividend Yield % is 1.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Obsidian Therapeutics's current Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Obsidian Therapeutics stock overvalued right now?
Obsidian Therapeutics (OBX) has a current Dividend Yield % of 0.00%. The current Dividend Yield % is 0.00%. Obsidian Therapeutics' overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For Obsidian Therapeutics (OBX), the current Dividend Yield % is 0.00% as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor infiltrating lymphocytes (TIL) cell therapies for the treatment of patients with solid tumors. The company's proprietary cytoDRiVE platform is versatile and allows it to leverage drug responsive domains to control protein function, with its initial focus on TIL cell therapies developed from this platform (cytoTILs). The company's flagship product candidate, OBX-115, is a novel, genetically engineered, autologous TIL cell therapy currently in a Phase 2 clinical trial for the treatment of melanoma and a Phase 1 clinical trial for the treatment of non-small cell lung cancer.
8GF Score
Get the complete analysis for OBX
Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OBX has been successfully added to your 
